RxDoctor Payments Data

Alejandro Montoya, MD

Family Medicine · Kansas City, MONPI 1740719749

Payments from drug & device makers

$6,795in general payments, 2019–2025

Across 408 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$905
  • Lilly USA, LLC$771
  • Novo Nordisk$750
  • Abbott$593
  • Pfizer$569
  • AstraZeneca$506
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,795100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,795 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$71,574
Medicare patients
329
Services billed
1,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$71,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$66,423
MounjaroTirzepatide51$61,341
JardianceEmpagliflozin37$50,563
RybelsusSemaglutide31$41,694
XareltoRivaroxaban38$35,548
FarxigaDapagliflozin Propanediol33$25,878
OzempicSemaglutide21$24,255
JanuviaSitagliptin Phosphate21$21,613
LinzessLinaclotide22$20,883
ShingrixVaricella-Zoster Ge/As01b/Pf82$18,096
Tresiba Flextouch U-100Insulin Degludec13$11,057
ArexvyRsvpref3 Antigen/As01e/Pf29$8,039
Gabapentin423$7,846
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix, Arexvy$263$92,558191 claims
PfizerEliquis, Abrysvo$569$75,43695 claims
Novo NordiskRybelsus, Ozempic$750$65,94952 claims
Lilly USA, LLCMounjaro$771$61,34151 claims
Boehringer IngelheimJardiance$328$50,56337 claims
Johnson & JohnsonXarelto$54$35,54838 claims
AstraZenecaFarxiga, Symbicort$506$32,12052 claims
MerckJanuvia$128$21,61321 claims
AbbVieLinzess$905$20,88322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →